Status of thyroid autoantibodies among Nigerian vitiligo patients


  • Collins Amadi Department of Chemical Pathology and Metabolic Medicine, University of Port Harcourt Teaching Hospital, Port Harcourt, Nigeria
  • Ehimen P. Odum Department of Chemical Pathology and Metabolic Medicine, University of Port Harcourt Teaching Hospital, Port Harcourt, Nigeria



Nigeria, Age, Sex, Vitiligo, Thyroid autoantibodies


Background: The prevalence of thyroid autoantibodies among vitiligo patients is higher than the general population. This study was therefore aimed to evaluate the status of thyroid autoantibodies in Nigerian patients with vitiligo.

Methods: A retrospective study of thyroid autoantibody test parameters of vitiligo patients who visited the Department of Chemical Pathology and Metabolic Medicine of the University of Port Harcourt Teaching Hospital between 1st January 2012 and 31st December 2016 was undertaken to evaluate the status of thyroid autoantibody. Data collected irrespective of vitiligo variant were age, sex, serum thyroid stimulating hormone (TSH), thyroid peroxidase antibody (anti-TPO) titers and thyroglobulin antibody (anti-Tg) titers. The analysis was done using Shapiro-Wilk, descriptive statistics, chi-square, and Fisher’s exact, two-sample t-test. The level of p<0.05 was considered significant.  

Results: There were a total of 102 subjects with 40 (39.2%) males and 62 (60.8%) females. Subjects’ age ranged from 4–61 with a median value of 23 years. The mean serum TSH, anti-TPO and anti-Tg were 2.6 IU/ml, 64.6 IU/ml, and 55.2 IU/ml respectively. Positive thyroid autoantibodies titers was documented in 35 (34.3%; <0.001) subjects. Anti-TPO and anti-Tg positive titers were detected in 34 (33.3%) and 19 (18.6%) subjects respectively, while autoimmune thyroid disease was observed in 20 (19.6%) of the vitiligo subjects.

Conclusions: Thyroid autoantibodies are more prevalent among vitiligo patients than the general population. Regular screening for these thyroid autoantibodies should be made compulsory in the management of patients with vitiligo.


Metrics Loading ...

Author Biography

Collins Amadi, Department of Chemical Pathology and Metabolic Medicine, University of Port Harcourt Teaching Hospital, Port Harcourt, Nigeria

Consultant Chemical Pathologist, department of Chemical Pathology.


Taieb A, Picardo M. Vitiligo. N Engl J Med. 2009;360(2):160-9.

Jishna P, Binitha MP, Abdul Latheef EN, Anikumari VP. Prevalence of thyroid dysfunction and anti-thyroid peroxidase antibodies in vitiligo patients. Int J Res Dermatol. 2017;3(1);140–4.

Onayemi O, Isezuo SA, Njoku CH. Prevalence of different skin conditions in an outpatient setting in north-west Nigeria. Int J Dermatol. 2005;44(1):7–11.

Altraide DD, George IO, Otike-Odibe B. Vitiligo: A hospital based study in southern Nigeria. Port Harcourt M J. 2009;4(2).

Kovacs SO. Vitiligo. J Am Acad Dermatol. 1998;38(5):647–66.

Robert P. Ueber die Vitiligo. Dermatologica. 1941;84:317–9.

Malhota N, Dytoc M. The Pathogenesis of Vitiligo. J Cutan Med Surg. 2013;17(3):153-72.

Njoo MD, Westerhof W. Vitiligo Pathogenesis and treatment. Am J Clin Dermatol. 2001;2(3):167–81.

Ongenae K, Geel N, Naeyaert JM. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res. 2003;16(2).

Mandry RC, Ortiz LJ, Lugo-somolinos A, Sanchez JL. Organ-specific autoantibodies in vitiligo patients and their relatives. Int J Dermatol. 1996;35(1):18-21.

Hegedus L, Heidenheim M, Gervil M, Hjalgrim H, Hoeier-Madsen M. High frequency of thyroid dysfunction in patients with Vitiligo. Acta Dem Venereol. 1994;74(2):120–3.

Dave S, D’Souza M, Thapp DM. High frequency of thyroid dysfunction in Indian patients With Vitiligo. Indian J Dermatol. 2003;48(2):68–72.

Okosieme OE, Taylor RC, Ohwovoriole AE, Parkes AB, Lazarus JH. Prevalence of thyroid antibodies in Nigerian patients. Q J Med. 2007;100(20):107–12.

Topal IO, Duman H, Gundor S, Kocaturk E, Can PK. Evaluation of the clinical and sociodemographic features of Turkish patients with vitiligo. Acta Dermatovenereol Croat. 2016;24(2);124–9.

Narita T, Oisio N, Fukai K, Kabashima K, Kawa A, Suzuki T. Generalized vitiligo and associated autoimmune diseases in Japanese patients and their families. Allergol Int. 2011;60:505–8.

Akay BN, Bozkir M, Anadolu Y, Gullus S. Epidemiology of vitiligo, associated autoimmune diseases and audiological abnormalities: Ankara study of 80 patients in Turkey. J Eur Acad Dermatol Venereol. 2010;24:1141-50.

Gang S, Mahajan V, Mehta KS, Gauhan PS, Gupta M, Yadav RS, et al. Vitiligo and associated disorders including autoimmune diseases: A prospective study of 200 Indian patients. Pigment Int. 2015;2:91–6.

Kumar KV, Priya S, Sharma R, Kapoor U, Saini M, Bisht YS. Autoimmune thyroid disease in patients with vitiligo: prevalence study in India. Endocr Pract. 2012;18(2):194–9.

Ogbara AO, Kuku SF. Epidemiology of thyroid diseases in African. Indian Endocrinol Metab. 2011;15(2):82-8.

Vrijman C, Kroon MV, Limpens J, Leeflang MM, Luiten RM, Van Der Veen JP, et al. The prevalence of thyroid disease in patients with vitiligo: a systematic review. Br J Dermatol. 2012;167(6):1224–35.






Original Research Articles